BioStock: Successful outcome of Chordate Medical’s warrant

Chordate Medical receives 35.6 MSEK before issue costs through the exercise of the warrants of series TO7. The subscription rate was 99.23 per cent and major shareholders exercised all their warrants. BioStock contacted CEO Anders Weilandt for a comment.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/11/successful-outcome-of-chordate-medicals-warrant/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se